FDA suspends (and promptly restarts) clinical trial for new cancer therapy
Bringing a new medical therapy to market is rarely a straightforward task, as a biotech company called Juno Therapeutics learned firsthand. Juno specializes in CAR-T therapy, which uses genetic engineering to teach a patient’s own immune system to destroy cancer cells. Unfortunately, 3 of the 129 patients who had received this treatment in a clinical trial recently died from excessive brain swelling, prompting the FDA to … Continue reading FDA suspends (and promptly restarts) clinical trial for new cancer therapy
